Docoh
Loading...

BCLI Brainstorm Cell Therapeutics

Employees

Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


The 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Brainstorm Cell Therapeutics Inc. (the “Company”) was held virtually via the internet on November 10, 2020 to consider and vote on the proposals set forth below each of which is described in greater detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on October 1, 2020. The following actions were taken at the Annual Meeting:

1. The seven nominees (listed below) for election to the Company’s Board of Directors were elected to hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal, based upon the following votes:

Votes ForVotes
Withheld
Votes
Against
AbstentionsBroker
Non-Votes
Sankesh Abbhi9,346,018125,190N/AN/A13,053,806
Dr. Irit Arbel8,216,0581,255,150N/AN/A13,053,806
Dr. June S. Almenoff9,360,443110,765N/AN/A13,053,806
Dr. Anthony Polverino9,046,379424,829N/AN/A13,053,806
Dr. Jacob Frenkel9,261,030210,178N/AN/A13,053,806
Malcolm Taub9,043,406427,802N/AN/A13,053,806
Uri Yablonka9,314,574156,634N/AN/A13,053,806



2. The proposal to approve amendments to the Company’s 2014 Stock Incentive Plan and the Company’s 2014 Global Share Option Plan to increase the shared pool of shares available for issuance under the Company’s current equity plans by 1,600,000 additional shares (from 4,000,000 to 5,600,000 shares) of Company Common Stock was approved, based upon the following votes:

Votes ForVotes WithheldVotes AgainstAbstentionsBroker Non-Votes
6,248,132N/A3,061,287161,78913,053,806



3. The proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the Company’s current fiscal year was approved, based upon the following votes:

Votes ForVotes WithheldVotes AgainstAbstentionsBroker Non-Votes
22,126,237N/A202,261196,516N/A